Investors & Media

Corporate Profile

We are a clinical stage chemoprotection oncology company focused on developing medicines to make chemotherapy safer and thereby more effective to save more patients’ lives.

ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, focusing exclusively on treating patients with p53-mutated cancers.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • June 29, 2022
    Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
  • May 19, 2022
    Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
  • May 17, 2022
    Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference


  • June 29, 2022 at 8:00 AM EDT

    Aileron Therapeutics Phase 1b Non-Small Cell Lung Cancer Interim Analysis Conference Call

    Read More
  • May 25, 2022 at 1:30 PM EDT

    H.C. Wainwright Global Investment Conference

    Read More

To develop a targeted drug that prevents chemotherapy-induced side effects to help patients fight cancer more effectively with a better quality of life


To bring chemoprotection to all patients with p53-mutated cancer regardless of the type of cancer or chemotherapy